Advaccine Biopharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


1234»
  • ||||||||||  Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
    Review, Journal:  Vaccination is the most effective and best way to avoid the disease of COVID-19. (Pubmed Central) -  Sep 3, 2023   
    Among the vaccines that stimulate the host's immune system with the help of DNA are: undergoing Phase 2/3 trials including INO-4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada-COVID19 (AnGes, Inc.); GX-19 (Genexine, Inc.). BNT162b2
  • ||||||||||  Review, Journal:  Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). (Pubmed Central) -  Apr 4, 2023   
    Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.
  • ||||||||||  rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
    Enrollment closed:  Safety and Efficacy of BARS13 in the Elderly (clinicaltrials.gov) -  Feb 2, 2023   
    P2,  N=125, Active, not recruiting, 
    Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention. Enrolling by invitation --> Active, not recruiting
  • ||||||||||  rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
    Journal:  RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. (Pubmed Central) -  Dec 20, 2022   
    A 15 amino acid sequence (FP4) within the F2 region of pre-F served as a CD4 Th epitope to facilitate the anti-G antibody response. Collectively, such a combination of the FP4 peptide with the G protein and CsA provides a novel strategy for developing a safe and maximally effective recombinant G protein-containing RSV vaccine.
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
    Enrollment change, Trial withdrawal, Combination therapy:  Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) -  Nov 17, 2022   
    P1,  N=0, Withdrawn, 
    Collectively, such a combination of the FP4 peptide with the G protein and CsA provides a novel strategy for developing a safe and maximally effective recombinant G protein-containing RSV vaccine. N=160 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) -  Oct 13, 2022   
    P2/3,  N=1308, Terminated, 
    N=160 --> 0 | Not yet recruiting --> Withdrawn N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health.
  • ||||||||||  rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
    Enrollment status, Trial completion date, Trial primary completion date:  Safety and Efficacy of BARS13 in the Elderly (clinicaltrials.gov) -  Sep 22, 2022   
    P2,  N=125, Enrolling by invitation, 
    N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health. Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Mar 2024
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
    Trial completion date, Trial primary completion date, Combination therapy:  Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) -  Aug 22, 2022   
    P1,  N=160, Not yet recruiting, 
    Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Mar 2024 Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    INO-4800 ? (Twitter) -  Aug 20, 2022   
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Ino-4800! (Twitter) -  Mar 28, 2022   
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Trial completion:  Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) -  Mar 8, 2022   
    P1,  N=120, Completed, 
    These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens. Active, not recruiting --> Completed
  • ||||||||||  Review, Journal:  Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. (Pubmed Central) -  Mar 5, 2022   
    Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    @InovioPharma Ino-4800 (Twitter) -  Dec 27, 2021